D
Roivant Sciences Ltd. ROIV
$11.92 $0.110.93% NASDAQ
Recommendation
Prev Close
$11.76
Volume
4,902,282
Avg Vol (90D)
5,821,918
Market Cap
$8.02B
Dividend & Yield
--
52-Week Range
$8.73 - $13.06
P/E (TTM)
--
EPS (TTM)
-$0.7041
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Trump Index: 6 Companies Linked to Trump’s Cabinet Worth Watching
1/28/2025 - MarketBeat
3 Stocks to Buy Now, According to the Technical Analysis
8/21/2025 - TipRanks Financial Blog
Invesco Ltd. Increases Stock Position in Roivant Sciences Ltd. (NASDAQ:ROIV)
8/18/2025 - MarketBeat
Nuveen LLC Takes $31.99 Million Position in Roivant Sciences Ltd. (NASDAQ:ROIV)
8/17/2025 - Ticker Report
Vanguard Group Inc. Has $411.35 Million Stock Position in Roivant Sciences Ltd. (NASDAQ:ROIV)
8/17/2025 - MarketBeat
Roivant Sciences: Vant Model And IMVT-1402 Create A 2025 Catalyst Stack
8/15/2025 - SeekingAlpha
Roivant Sciences: Vant Model And IMVT-1402 Create A 2025 Catalyst Stack
8/15/2025 - Seeking Alpha - Long Ideas
Roivant Sciences (ROIV, $11.96) Moving Average Convergence Divergence (MACD) Histogram turned positive on August 13, 2025
8/14/2025 - Tickeron - Stocks
Entropy Technologies LP Purchases Shares of 99,973 Roivant Sciences Ltd. (NASDAQ:ROIV)
8/13/2025 - MarketBeat
Roivant Sciences' (ROIV) Aggressive Buybacks Amid Losses: Commitment to Shareholders or Growth Uncertainty?
8/13/2025 - Simply Wall St
Roivant Sciences (ROIV) Stock Rises on Analyst Upgrade
8/12/2025 - GuruFocus
Why Roivant Sciences Stock Bounced Back on Tuesday
8/12/2025 - Fool.com Headlines
Leerink Partners Keeps Their Buy Rating on Roivant Sciences (ROIV)
8/12/2025 - TipRanks Financial Blog
Roivant Sciences (NASDAQ:ROIV) Shares Gap Down Following Weak Earnings
8/12/2025 - MarketBeat
Guggenheim Sticks to Its Buy Rating for Roivant Sciences (ROIV)
8/12/2025 - TipRanks Financial Blog
Roivant Sciences (NASDAQ:ROIV) Announces Earnings Results, Misses Estimates By $0.07 EPS
8/12/2025 - MarketBeat
Bank of America Securities Sticks to Their Hold Rating for Roivant Sciences (ROIV)
8/12/2025 - TipRanks Financial Blog
Roivant Sciences Ltd (ROIV) Q1 2025 Earnings Call Highlights: Strong Cash Position and ...
8/12/2025 - GuruFocus
Q1 2025 Roivant Sciences Ltd Earnings Call Transcript
8/12/2025 - GuruFocus
Decoding Roivant Sciences Ltd (ROIV): A Strategic SWOT Insight
8/12/2025 - GuruFocus
Roivant Sciences (ROIV) Stock Movement Explained
8/11/2025 - GuruFocus
Why Roivant Sciences Stock Was Slipping on Monday
8/11/2025 - Fool.com Headlines
Roivant Sciences (ROIV) Eyes Busy Fall with New Developments
8/11/2025 - GuruFocus
Roivant Sciences Ltd. 2025 Q1 - Results - Earnings Call Presentation
8/11/2025 - SeekingAlpha
Roivant Sciences Ltd. (ROIV) Q1 2025 Earnings Call Transcript
8/11/2025 - Seeking Alpha: Transcripts
Income Statement
Total Revenue (TTM)
$23.23M
EBITDA (TTM)
-$1.15B
EBIT (TTM)
-$1.16B
Net Income (TTM)
-$490.63M
Balance Sheet
Total Assets (Q)
$5.03B
Total Debt (Q)
$99.69M
Total Liabilities (Q)
$216.70M
Book Value Per Share (Q)
$6.37
Cash Flow
Cash from Operations (TTM)
-$584.20M
Cash from Investing (TTM)
$442.55M
Cash from Financing (TTM)
-$637.87M
Net Change in Cash (TTM)
-$780.26M
Filings
Filing Date
Monday, August 11, 2025
Period Date
Monday, June 30, 2025
Next Filing
Week of Nov 10 and 14 (est)
Price History
Loading...
Beta
0.88
7-Day Total Return
3.03%
30-Day Total Return
3.03%
60-Day Total Return
10.78%
90-Day Total Return
20.89%
Year to Date Total Return
-1.32%
1-Year Total Return
1.10%
2-Year Total Return
8.76%
3-Year Total Return
223.91%
5-Year Total Return
--
52-week Low
Apr 07, 2025 - $8.73
52-week High
Sep 09, 2024 - $13.06
Valuation
Market Cap
$8.02B - Mid Cap
Enterprise Value
$4.08B
Price/Sales (TTM)
344.87
Price/Book (Q)
1.85
Dividends and Shares
Shares Outstanding
680.29
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
roivant.com
Phone Number
Address
11-12 St. James's Square
Suite 1 - 3rd Floor
London, SW1Y 4LB
Country
United Kingdom
Year Founded
2014
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates... more
NASDAQ 08/22/2025 4:00PM Eastern Quotes delayed